AbbVie is a research-based pharmaceutical manufacturer that makes a range of medications. Learn the latest information and analysis on the company, ABBV stock price today, stock news, how much one share costs and other information to help you make investment decisions.
Check out Gainy to see insights on stock prices and more.
AbbVie was officially founded in 2013, but it came into existence when it split from its parent company Abbott Laboratories, founded in 1888. The company makes the world's best-selling drug Humira (used for autoimmune diseases, rheumatoid arthritis and other diseases), which brought $19.17 billion in 2019 alone.
This is a very high-quality business with strong cash flow, one of the companies that should do well if we are to go into a recession. Providing a good dividend yield of almost 4%, this stock should feel like a safe haven.
The AbbVie stock price may be slightly overvalued to buy at $150, but having reached $175.91 in April 2022 one can expect ABBV to beat its record soon.
Check back to this page for the ABBV stock quote or download Gainy to to see if ABBV fits your portfolio and investment goals, get other stock quotes and personal recommendations.
